44 related articles for article (PubMed ID: 38633828)
1. Diagnostic and prognostic value of preoperative
Lee JY; Yoon SM; Kim JT; Kim KB; Kim MJ; Park JG; Lee TG; Lee SJ; Koong SS; Han JH; Chae HB; Park SM; Youn SJ
Intest Res; 2017 Apr; 15(2):208-214. PubMed ID: 28522951
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
[TBL] [Abstract][Full Text] [Related]
4. Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer.
Al-Zubaidi M; Ong K; Viswambaram P; Bangash H; Boardman G; McCombie SP; Oey O; Swarbrick N; Redfern A; Ong J; Gauci R; Low R; Hayne D
BJUI Compass; 2024 Apr; 5(4):473-479. PubMed ID: 38633828
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of
Voskuilen CS; Schweitzer D; Jensen JB; Nielsen AM; Joniau S; Muilwijk T; Necchi A; Azizi M; Spiess PE; Briganti A; Bandini M; Goffin K; Bouchelouche K; van Werkhoven E; Shariat SF; Xylinas E; Azawi NH; Ku JH; Foerster B; van Rhijn BWG; Vegt E; Hendricksen K
Eur Urol Oncol; 2020 Feb; 3(1):73-79. PubMed ID: 31591037
[TBL] [Abstract][Full Text] [Related]
9. Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database.
Viswambaram P; McCombie SP; Hawks C; Wallace DMA; Sengupta S; Hayne D
Asia Pac J Clin Oncol; 2023 Jun; 19(3):290-295. PubMed ID: 36352543
[TBL] [Abstract][Full Text] [Related]
10.
Al-Zubaidi M; Viswambaram P; McCombie S; Liow E; Lenzo N; Ferguson T; Redfern AD; Gauci R; Hayne D
BMJ Open; 2022 Apr; 12(4):e060478. PubMed ID: 35428649
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
Moussa M; Chakra MA; Saad W; Dellis A; Papatsoris A
Urol Oncol; 2021 Dec; 39(12):833.e9-833.e17. PubMed ID: 34059435
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.
Witjes JA; Compérat E; Cowan NC; De Santis M; Gakis G; Lebret T; Ribal MJ; Van der Heijden AG; Sherif A;
Eur Urol; 2014 Apr; 65(4):778-92. PubMed ID: 24373477
[TBL] [Abstract][Full Text] [Related]
14. Intravesical therapies for bladder cancer - indications and limitations.
Logan C; Brown M; Hayne D
BJU Int; 2012 Dec; 110 Suppl 4():12-21. PubMed ID: 23194118
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
